The Prevalence of Amyloid Positivity by Age, APOE Genotype and Cognitive Status -Implications for the Diagnosis of Alzheimer's Disease

Philip Scheltens Alzheimer Center VU University Medical Center Amsterdam





Disclosures

The Alzheimer Center VUmc has received unrestricted funding from:

 Aegon, Alzheimer Nederland, VUmc Fonds, Heineken Nederland, Kroonenberg NV, Rabobank Amsterdam, Genootschap tot Steun Alzheimercentrum, Alzheimer Rally, and many others

Contract research partners:

• GE Healthcare, Piramal Imaging, Merck, Nutricia, Probiodrug, EIP Pharma, Roche AG and Boehringer Ingelheim

Grant funding:

• NWO, ZonMW, CVON, EU-FP7, EU-JPND, EU-IMI, ISAO, Alzheimer Nederland, Dioraphte, Gieskes Strijbis

Dr Scheltens receives no personal compensation from any of the above or others except the VUmc.





Outline

- Background
- Prevalence of amyloid in normals and MCI
 - Influence of APOE
- Prevalence of amyloid in demented
 - Influence of APOE
- Diagnosis and prognosis
- Ongoing work
- Conclusions




Most dementias are proteinopathies

Dementia	Αβ	tau	p-tau	a-synuclein	TDP-43
AD	Х	Х	Х	Х	
DLB	Х	Х		Х	
FTD	Х	Х			Х
PSP		Х			
CBD	Х	Х			
СТЕ	Х		Х	Х	Х

Table 1: pathologic proteins underlying some of the main dementia types





Alzheimer: 3 fundamental processes



Amsterdam

Amyloid in vivo







Abeta 1-42

VUmc

VU University Alzheimer Center Amsterdam

Entering a new era: the case of AD

- Prodromal AD: diagnosing AD before dementia
- Preclinical AD: AD without symptoms
- Clinical trials include earlier populations; target protein needs to be identified
- Patients want to be informed
- Dementia field follows the oncology pathway: Personalized / precision medicine
- Emphasizes the need for biomarkers for diagnosis, tracking disease and measure effect
- Healthcare providers and payors need to be informed and prepared.



[¹⁸F] labeled Amyloid PET tracers

Florbetapir (Amyvid)	
Florbetaben (Neuraceq)	
Flutemetamol (Vizamyl)	





Amyloid binding is associated with decline

OPEN

Molecular Psychiatry (2014) 19, 1044–1051 © 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14

www.nature.com/mp

ORIGINAL ARTICLE Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

PM Doraiswamy¹, RA Sperling², K Johnson², EM Reiman³, TZ Wong¹, MN Sabbagh⁴, CH Sadowsky⁵, AS Fleisher^{3,6}, A Carpenter⁷, AD Joshi⁷, M Lu⁷, M Grundman^{6,8}, MA Mintun⁷, DM Skovronsky⁷, MJ Pontecorvo⁷ For the AV45-A11 Study Group⁹





Figure. Paired Representative Florabetapir-PET Scans and β-Amyloid Antibody 4G8 Immunohistochemistry Photo Micrographs









Prevalence of amyloid positivity

- Subject-level meta-analysis
 - Non-demented subjects (Jansen et al JAMA 2015)
 - Normal cognition, subjective cognitive impairment, mild cognitive impairment
 - Amyloid assessed in CSF or by PET imaging
 - Data from 55 studies
 - Demented subjects (Ossenkoppele et al JAMA 2015)
 - AD and other dementias
 - Amyloid assessed by PET imaging
 - Data from 29 studies






Prevalence amyloid positivity in nondemented subjects




VU University Alzheimer Center Amsterdam

Prevalence amyloid positivity in nondemented subjects




VU University Alzheimer Center Amsterdam


VUmo























Implications for screening for amyloid positivity-1

eTable 6. Number needed to screen according to age, cognitive status and *APOE* genotype

Group	50 yr	60 yr	70 yr	80 yr	90 yr
Number neede	ed to screen if APOE	genotype is know	'n		
Participants wi	th normal cognition				
Total group	10.0 (7.7-12.5)	6.3 (5.3-7.7)	4.3 (3.7-5.3)	3.0 (2.6-3.6)	2.3 (2.0-2.7)
APOE-ε4-	16.7 (11.1-25.0)	10.0 (7.7-14.3)	5.9 (4.8-7.1)	3.6 (3.0-4.3)	2.4 (2.0-3.0)
APOE-ε4+	6.7 (4.8-10.0)	3.4 (2.7-4.5)	2.1 (1.9-2.4)	1.5 (1.4-1.6)	1.2 (1.1-1.3)
<i>ΑΡΟΕ</i> -ε4ε4	2.8 (2.0-4.0)	1.7 (1.4-2.4)	1.3 (1.1-1.7)	1.1 (1.0-1.4)	1.0 (1.0-1.3)
Patients with N	<i>ICI</i>				
Total group	3.7 (3.3-4.3)	2.7 (2.4-3.0)	2.0 (1.9-2.2)	1.7 (1.5-1.8)	1.4 (1.3-1.5)
APOE-ε4-	5.3 (4.2-7.1)	3.8 (3.2-4.5)	2.9 (2.6-3.2)	2.2 (2.0-2.5)	1.8 (1.6-2.1)
APOE-ε4+	2.5 (2.1-3.0)	1.8 (1.6-2.0)	1.4 (1.4-1.5)	1.2 (1.2-1.3)	1.1 (1.1-1.2)
ΑΡΟΕ-ε4ε4	1.6 (1.3-2.1)	1.3 (1.2-1.4)	1.1 (1.1-1.2)	1.1 (1.0-1.2)	1.0 (1.0-1.1)



VU University Alzheimer Center Amsterdam

Implications for screening for amyloid positivity-2


eTable 6. Number needed to screen according to age, cognitive status and *APOE* genotype

Group	50 yr	60 yr	70 yr	80 yr	90 yr
Number of pa	Number of participants needed for APOE genotyping in order to find 1 amyloid positive participant *				
Participants with normal cognition					
APOE-ε4-	23.6 (15.8-35.5)	14.2 (10.9-20.3)	8.3 (6.8-10.1)	5.1 (4.3-6.2)	3.5 (2.8-4.3)
APOE-ε4+	22.6 (16.9-33.9)	11.7 (9.2-15.4)	7.1 (6.3-8.1)	5.0 (4.6-5.5)	4.1 (3.9-4.4)
ΑΡΟΕ-ε4ε4	89.6 (64.5- 1 29.0)	55.6 (45.4-76.8)	40.3 (35.8-54.7)	35.4 (32.9-43.6)	34.3 (32.6-41.4)
Patients with MCI					
ΑΡΟΕ-ε4-	9.9 (7.9-13.5)	7.3 (6.1-8.6)	5.4 (4.8-6.1)	4.2 (3.7-4.7)	3.4 (3.0-3.9)
<i>ΑΡΟΕ</i> -ε4+	5.3 (4.5-6.4)	3.8 (3.5-4.2)	3.0 (2.9-3.2)	2.6 (2.5-2.7)	2.4 (2.3-2.5)
<i>ΑΡΟΕ</i> -ε4ε4	14.7 (12.3-19.7)	11.9 (11.1-13.1)	10.6 (10.0-11.6)	9.9 (9.6-11.0)	9.7 (9.5-10.6)

* If *APOE* genotype is unknown, participants need to be screened for this first. The number needed to screen now indicate the number of participants for whom *APOE* genotyping needs to be performed in order to find one participant with that *APOE*- ϵ 4 carrier status who is amyloid positive. It is calculated as the inverse of the point estimates for the prevalence of amyloid pathology multiplied by the *APOE*- ϵ 4 background prevalence in our sample.




VU University Alzheimer Center Amsterdam






ner Center





VU University Alzheimer Center Amsterdam


B Lifetime risk of Alzheimer disease and amyloid positivity by APOE genotype




VU University Alzheimer Center Amsterdam

VUIII

B Lifetime risk of Alzheimer disease and amyloid positivity by APOE genotype




B Lifetime risk of Alzheimer disease and amyloid positivity by APOE genotype




VU University Alzheimer Center Amsterdam

VUIII

B Lifetime risk of Alzheimer disease and amyloid positivity by APOE genotype



Relation with memory score




1a Frequency of memory impairment (z-score <= -1.28) in participants with normal cognition, n=2544 1b Frequency of memory impairment in participants with MCI, n=2960



Jansen et al in preparation

Relation with MMSE score




2a Frequency of low MMSE (MMSE <= 27) in participants with normal cognition, n=2885 2b Frequency of low MMSE in participants with MCI, n=4126

VU University Alzheimer Center

Amsterdam

VUm




Summary prevalence amyloid positivity in non-demented subjects


- Higher in MCI than in cognitively normal and SCI
- Strongly dependent on age and APOE genotype
- Amyloid positivity in cognitively normal subjects precedes AD-type dementia by >25 years




Prevalence amyloid positivity in demented subjects



VU University Alzheimer Center Amsterdam










Prevalence amyloid positivity in demented subjects






Effect amyloid positivity on MMSE score in non-AD dementia

	Amyloid positive	Amyloid negative	P-value
Any dementia	20.6	23.2	<0.001
DLB	19.6	25.3	<0.001
VaD	19.5	22.3	<0.05
FTLD	22.4	23.9	0.17
CBS	21.6	23	0.48



Ossenkoppele et al JAMA 2015

Diagnostic accuracy amyloid positivity for distinction from AD





Summary prevalence amyloid positivity in demented subjects

- Amyloid positivity converges at high age across dementias
- Not all subjects with a clinical AD diagnosis are amyloid positive
- Clinical diagnosis AD and e4+:
 - >90% amyloid positive
- Clinical diagnosis AD and e4-:
 - At age 70: 90% amyloid positive
 - At age 90: 65% amyloid positive
- Amyloid positivity common in non-AD dementia
- Odds ratio decreases for clinical dementia subtype diagnosis
- Clinical relevance?
- Misdiagnosis?
- Co-morbidity?




Diagnosis and prognosis

- Amyloid markers for diagnosis
- Injury markers for prognosis
- AD stages:

AD stage	Cognition	AD biomarker
Preclinical stage	Normal	Abnormal
MCI stage	MCI	Abnormal
Dementia stage	Dementia	Abnormal




Prognosis preclinical AD (n=311): progression to MCI



Vos et al Lancet Neurology 2013

Prognosis prodromal AD (n=1607): progression to AD-type dementia



VUn

Vos et al Brain 2015

Ineke A. van Rossum, MD Stephanie J.B. Vos, MSc Leah Burns, MPH Dirk L. Knol, PhD Philip Scheltens, MD, PhD Hilkka Soininen, MD, PhD Lars-Olof Wahlund, MD, PhD Harald Hampel, MD, PhD Magda Tsolaki, MD, PhD Lennart Minthon, MD, PhD Gilbert L'Italien, PhD Wiesje M. van der Flier, PhD Charlotte E. Teunissen, PhD Kaj Blennow, MD, PhD Frederik Barkhof, MD, PhD Daniel Rueckert, PhD Robin Wolz, PhD Frans Verhey, MD, PhD Pieter Jelle Visser, MD, PhD

Injury markers predict time to dementia in subjects with MCI and amyloid pathology


Figure 2


Veuroscie

msterda


Decline in Mini-Mental State Examination (MMSE) score in subjects with mild cognitive impairment (MCI) and abnormal CSF A β_{1-42} according to CSF total tau (t-tau) and hippocampal volume

A CSF t-tau





Prognosis AD dementia stage



Wallin et al Neurology 2010

Mrs H, 1911



100 plus study


- Grew up in Rotterdam
- At age 28 she moved to Groningen
- Grew up in a familiy of musicians and became a musician herself (piano teacher)
- Oldest of 6 children
- 3 children
- Lab: ApoE 3/3
- MMSE 27/30


- One sigaret per week for 14 years (till age of 50)
- 69-90 years:
 - 3 glasses of (white/red) wine a week
- wide social network, lots of friends





Neuropsychological examination












Mrs H. 1911; MTA 2/2; Faz 2; ApoE 3/3











Mrs H. 1911; MMSE 27; amyloid angiopathy


















Mrs H, 1911. C¹¹PIB at 103







Pathology

Braak 3 tau/tangles Thal 3/5 plaques. CAA 1/ 3 (Thal).

Frontal abeta (10x)




Temporal Abeta





Heritability



White matter lesions in monozygotic twin pair

Correlation in PET amyloid binding between monozygotic twins

twin1

40

1.00

.80

.20

.00

.00

.20

twin2

Konijnenberg/Ten Kate in preparation

.60



0

.80

0

1.00





Conclusions

- Field has changed dramatically due to biomarkers
- Amyloid positivity strongly related to age and APOE
- In normal aging and dementia(s)
- Diagnostic information decreases with age
- By itself not diagnostic for AD and not be used outside of clinical context
- May be used to select patients for interventions



Acknowledgements

VU University Medical Centre

Daniela Bertens Ineke van Rossum Elles Konijnenberg Anouk den Braber Mara Ten Kate Nienke Legdeur Lisa Vermunt **Rik Ossenkoppele** Dirk Knol Wiesje van der Flier University Maastricht Willemijn Janssen Stephanie Vos Isabella Bos Babette Reijs Frans Verhey

Pieter Jelle Visser



